Cargando…

Remote Programming of Cochlear Implants

OBJECTIVE: This study investigated the safety and efficacy of remote programming of cochlear implants. STUDY DESIGN: Single-subject design SETTING: Four North American clinical sites PATIENTS: Forty cochlear implant recipients aged 12 years or older INTERVENTION: Subjects had their cochlear implants...

Descripción completa

Detalles Bibliográficos
Autores principales: Slager, Heidi K., Jensen, Jamie, Kozlowski, Kristin, Teagle, Holly, Park, Lisa R., Biever, Allison, Mears, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380526/
https://www.ncbi.nlm.nih.gov/pubmed/30741905
http://dx.doi.org/10.1097/MAO.0000000000002119
Descripción
Sumario:OBJECTIVE: This study investigated the safety and efficacy of remote programming of cochlear implants. STUDY DESIGN: Single-subject design SETTING: Four North American clinical sites PATIENTS: Forty cochlear implant recipients aged 12 years or older INTERVENTION: Subjects had their cochlear implants programmed at a location that was remote from their audiologist using telecommunication with and without the support of a facilitator. MAIN OUTCOME MEASURES: Consonant-Nucleus-Consonant (CNC) word scores and the Speech, Spatial, and Qualities of Hearing Scale-C (SSQ-C) were compared using the subject's in-office MAP (program) and MAPs programmed remotely with and without the assistance of a facilitator. Additional subjective preference data were gathered from subjects and audiologists via questionnaires. RESULTS: MAPs programmed via the three different models did not yield significantly different group mean CNC word scores. No device/procedure-related adverse events occurred. SSQ-C questionnaire results indicated that recipients received similar subjective benefit from familiar in-office, remote-facilitated, and remote-unassisted MAPs. CONCLUSIONS: Remote programming is an effective means of cochlear implant service delivery. The practice was approved by the FDA on November 17, 2017 supported by the results of this study.